8-K: CervoMed Announces Positive Phase 2b Trial Results and Plans Phase 3 Study for Dementia with Lewy Bodies

CervoMed reports positive results from the extension phase of its Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) and plans to initiate a Phase 3 trial in mid-2026.

Summary

• CervoMed Inc. reported its financial results for the first quarter ended March 31, 2025, and provided corporate updates.
• Positive 16-week results from the extension phase of the RewinD-LB trial showed improvements on the Clinical Dementia Rating Sum of Boxes (CDR-SB) (p<0.001 v. old capsules; p=0.003 v. placebo).
• The company plans to initiate a Phase 3 trial of neflamapimod in DLB in mid-2026, pending discussions with the FDA and available funding.
• CervoMed is initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke.
• As of March 31, 2025, CervoMed had approximately $35.2 million in cash, cash equivalents, and marketable securities.
• The company believes its current funds, along with remaining grant funds, will support operations into mid-2026.
• The net loss for the quarter was approximately $4.9 million, compared to a net loss of approximately $2.5 million for the same period in 2024.
• Grant revenue for the three months ended March 31, 2025, was approximately $1.9 million, compared to approximately $2.3 million for the same period in 2024.
• Research and Development (R&D) expenses for the three months ended March 31, 2025, were approximately $4.8 million, compared to approximately $2.8 million in 2024.
• General and Administrative (G&A) expenses were approximately $2.4 million during the three months ended March 31, 2025, versus approximately $2.1 million in the same period in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the promising clinical trial results and plans for Phase 3 development. However, the increased net loss and dependence on future funding introduce some uncertainty.

Positives

• Positive 16-week results from the extension phase of the RewinD-LB trial suggest potential for neflamapimod as a DLB treatment.
• The company is advancing neflamapimod into Phase 3 trials, indicating confidence in the drug's potential.
• Initiation of Phase 2a trials in other neurological disorders expands the potential applications of neflamapimod.
• Sufficient cash runway to fund operations into mid-2026 provides financial stability for ongoing development programs.
• The company was awarded a $21.0 million grant from the NIA to support the RewinD-LB trial and, in August 2024, CervoMed was awarded an additional $0.3 million under the grant.

Negatives

• The company reported a net loss of approximately $4.9 million for the first quarter of 2025, compared to a net loss of approximately $2.5 million for the same period in 2024.
• The Phase 3 trial is contingent on securing additional funding, which introduces uncertainty.
• The Phase 3 trial is planned for mid-2026, which is a long time away.

Risks

• Clinical trial results may not be replicated in later trials.
• Regulatory approval of neflamapimod is not guaranteed.
• The company's cash runway is dependent on achieving planned milestones and managing expenses.
• General economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts could impact the company's operations and financial results.

Future Outlook

CervoMed plans to initiate a Phase 3 trial in DLB in mid-2026, following a meeting with the FDA and subject to available funding. The company also plans to initiate a Phase 2a trial in patients with primary progressive aphasia in mid-2025 and has recently initiated a Phase 2a trial in patients recovering from ischemic stroke. The company expects to report 32-week results from the extension phase of the RewinD-LB trial in the second half of 2025.

Management Comments

• The first quarter of 2025 represented a tidal shift for CervoMed.
• We believe the evidence of slowed clinical progression demonstrated in the 16-week results from the extension phase of our RewinD-LB trial affirm our initial hypothesis of drug benefit, and explain the results from the initial phase of the trial reported in December 2024.
• More importantly, we believe the 16-week data demonstrate proof-of-concept for neflamapimod as a potential treatment for DLB, underscoring neflamapimods first-to-market potential for this devastating disease.
• We anticipate 32-week results from the extension phase in the second half of 2025 and are actively preparing for discussions with the U.S. Food and Drug Administration (FDA) regarding the design of our Phase 3 trial, which we plan to initiate in mid-2026.
• In parallel, in the near future we will be initiating a Phase 2 trial evaluating neflamapimod in patients with primary progressive aphasia (PPA), and recently initiated a Phase 2 trial in patients recovering from ischemic strokeimportant steps that we believe complement our lead DLB program, build on the compelling data seen so far, and expand our exploration of neflamapimods full therapeutic potential.
• I want to express my deep gratitude to our dedicated scientific team, as well as to the patients and caregivers participating in our clinical programs.

Industry Context

The development of treatments for age-related neurologic disorders, particularly DLB and FTD, represents a significant unmet medical need. CervoMed's focus on neflamapimod and its potential to address synaptic dysfunction positions the company to potentially capture a significant market share if the drug proves effective and receives regulatory approval.

Comparison to Industry Standards

• It is difficult to compare CervoMed's results directly to industry standards without knowing the specific details of other companies' clinical trials and financial situations.
• However, the company's focus on DLB and FTD aligns with the broader industry trend of developing treatments for neurodegenerative diseases.
• Companies like Biogen, Eli Lilly, and Roche are also investing heavily in this area, but their approaches and target populations may differ from CervoMed's.
• The $35.2 million in cash, cash equivalents, and marketable securities as of March 31, 2025, is a relatively small amount compared to larger pharmaceutical companies, but it is sufficient to fund the company's planned operations into mid-2026.

Stakeholder Impact

• Shareholders: The positive clinical trial results could increase shareholder value, but the need for additional funding introduces risk.
• Patients: Successful development of neflamapimod could provide a new treatment option for DLB and other neurological disorders.
• Employees: Advancement of the company's pipeline could create new job opportunities and enhance job security.
• Investors: The company's financial performance and clinical trial progress will influence investor confidence and future funding opportunities.

Next Steps

• Report 32-week results from the extension phase of the RewinD-LB trial in the second half of 2025.
• Obtain initial safety, biomarker and pharmacokinetic data from an ongoing trial in patients with mild-to-moderate DLB evaluating a twice daily regimen (80mg BID) of neflamapimod in the fourth quarter of 2025.
• Initiate a Phase 3 trial in DLB in mid-2026, following a meeting with the FDA and subject to available funding.
• Initiate a Phase 2a trial in patients with the nonfluent/agrammatic variant of PPA in mid-2025.
• Continue Phase 2a trial evaluating neflamapimod in patients recovering from ischemic stroke.

Key Dates

Keywords

neflamapimod, dementia with Lewy bodies, DLB, clinical trial, Phase 3, Phase 2b, RewinD-LB, CervoMed, neurologic disorders, financial results